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Abstract
In past 10 years, microRNAs (miRNAs) have gained scientific attention due to their 
importance in the pathophysiology of allergic diseases and their potential as biomark-
ers in liquid biopsies. They act as master post-transcriptional regulators that control 
most cellular processes. As one miRNA can target several mRNAs, often within the 
same pathway, dysregulated expression of miRNAs may alter particular cellular re-
sponses and contribute, or lead, to the development of various diseases. In this re-
view, we give an overview of the current research on miRNAs in allergic diseases, 
including atopic dermatitis, allergic rhinitis, and asthma. Specifically, we discuss how 
individual miRNAs function in the regulation of immune responses in epithelial cells 
and specialized immune cells in response to different environmental factors and res-
piratory viruses. In addition, we review insights obtained from experiments with mu-
rine models of allergic airway and skin inflammation and offer an overview of studies 
focusing on miRNA discovery using profiling techniques and bioinformatic modeling 
of the network effect of multiple miRNAs. In conclusion, we highlight the importance 
of research into miRNA function in allergy and asthma to improve our knowledge of 
the molecular mechanisms involved in the pathogenesis of this heterogeneous group 
of diseases.
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1  | INTRODUC TION
The human body is constantly subjected to an onslaught of allergens 
and environmental irritants. These particles can trigger immune and 
inflammatory responses leading to a variety of alterations in gene ex-
pression. In recent years, the study of non-coding RNAs has led to an 
increased understanding that gene regulation is more complex than 
previously imagined.1,2 Among other mechanisms, small non-coding 
microRNAs (miRNAs) have found themselves in the role of central 
regulators of post-transcriptional gene expression. The details of 
miRNA molecular function, biogenesis, and processing have been 
thoroughly described in several reviews1-4 and presented briefly in 
Figure 1. It should be highlighted that in mammalian cells miRNAs 
often initiate mRNA deadenylation followed by degradation of their 
target genes via imperfect binding to the 3′ untranslated regions of 
mRNAs. This imperfect binding leads to the suppression of multiple 
targets by one miRNA, while a single mRNA can be influenced by 
several miRNAs. There are several points to take into account when 
understanding miRNA nomenclature.5 (a) Novel miRNAs are named 
sequentially and currently over 2500 are verified. There are naming 
exceptions for “historical” miRNAs such as let-7 and lin-4 which were 
first discovered in C. elegans. (b) miRNA clusters are areas where two 
or more miRNAs are transcribed from adjacent miRNA genes (eg, 
miR17~92). (c) miRNA strands are named -5p or -3p indicating if 
they originate from the 5′ or 3′ arm of the hairpin and either may be 
responsible for regulating cellular processes (Figure 1). Nowadays, 
technological advances such as real-time PCR, microarray, and 
next-generation sequencing have simplified the identification and 
validation of miRNAs, allowing for the exponential growth of inves-
tigation of miRNAs as regulatory molecules in numerous research 
areas.
Although miRNAs were first discovered nearly thirty years ago, 
their detailed role in the immune system has only begun to be eluci-
dated in the past decade. While more thoroughly studied in cancer, 
recent research has reported alterations in miRNA expression in skin 
conditions and a variety of lung diseases, including, but not limited 
to: idiopathic pulmonary fibrosis, cystic fibrosis, chronic obstruc-
tive pulmonary disease, and asthma.6-10 The use of experimental 
F I G U R E  1   microRNA biogenesis and clinical sampling. (Left) miRNAs are transcribed in the nucleus by RNA polymerase II (RNA pol 
II) and processed by the enzymes Drosha and DiGeorge syndrome critical region 8 (DGCR8) from Pri- to Pre-miRNA. Exportin5 acts to 
export Pre-miRNAs to the cytoplasm where Dicer and the Dicer binding protein TRBP cut the hairpin to shorter duplexes. While the mature 
miRNA is incorporated into the miRNA induced silencing complex (miRISC) containing Ago2 and trinucleotide repeat-containing gene 6 
(TNRC6) proteins, the passenger strand is degraded. In the miRISC, the mature miRNA acts as a guide RNA for RISC proteins, of which 
Ago2 has the capacity to cleave mRNA if there is very high homology between the miRNA and the mRNA. If the homology is low, TNRC6 
activity predominantly leads to deadenylation and degradation or translational repression of the target mRNA. In addition, miRNAs can 
be incorporated into different types of secretory vesicles and exit to the extracellular space. (Right) miRNAs are found in cells, tissues and 
fluids throughout the body. In lung diseases, miRNA levels in fluids, for example serum, plasma and urine (either protein-bound, ie, free, or 
within extracellular vesicles), are often altered compared to healthy controls. This qualifies them to be used as non-invasive biomarker for 
lung diseases. Other examples of clinical sampling that would allow for the identification of miRNAs in asthma, atopic dermatitis and allergic 
rhinitis are illustrated figure
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systems, such as cell culture and mouse models, has furthered our 
knowledge of the mechanistic role of miRNAs in airway hyper-reac-
tivity, allergy and immune responses.2,4,11-13 Research into the role 
of miRNAs in allergy is expanding and many potential players have 
been identified in laboratory studies, but their actual role in human 
disease remains poorly understood.
This review highlights the recent steps toward a better under-
standing of the role of miRNAs in allergic diseases including atopic 
dermatitis (AD), allergic rhinitis (AR) and asthma. The importance of 
miRNA regulation in the pathogenesis of the aforementioned allergic 
diseases is supported by many studies, but also in other allergic dis-
eases such as food allergy or chronic rhinosinusitis the evidence for a 
role of miRNAs is emerging.4,10,13-29 Figure 2 provides an overview of 
miRNAs in cells and tissues that are associated with allergic diseases 
presented herein.
2  | HUMAN DISE A SE
2.1 | Atopic dermatitis
AD is a complex chronic inflammatory skin disease that is associated 
with skin barrier defects and activation of immune responses in the 
skin by environmental allergens and/or intrinsic factors.30 Although 
type 2 inflammatory responses and elevated IgE are known as the 
main characteristics of AD, some patients actually develop stronger 
T helper cell (Th) Th17/Th22 responses.31 Among other character-
istic features, activation of keratinocytes plays an important role in 
AD.30,32 Research on miRNAs in AD started with an array analysis of 
lesional skin samples from AD and psoriasis patients, representing, 
another inflammatory skin disease. The results of this early study 
suggested that alterations in miRNA levels in the skin of AD patients 
partially overlapped with that of psoriatic skin and included multiple 
miRNAs shown to be modulated in other inflammatory conditions.33 
For example, miR-21 and miR-146a were shown to be upregulated 
in the skin of psoriasis and AD patients.33 miR-146a was demon-
strated to inhibit many pro-inflammatory chemokines in keratino-
cytes through targeting multiple factors of the NF-κB pathway34-37 
and miR-146a-deficient mice developed stronger inflammation 
in both AD and psoriasis models.36,38 It has been shown that miR-
146a deficiency in mice leads to a defect in IgE production39,40 
and is linked to a Th1/Th17 skewing phenotype,41 suggesting that 
miR-146a is needed for the production of IgE and suppression of 
Th1/17-cell-mediated immune responses in mice. However, a nega-
tive relationship between miR-146a and IgE levels was observed in 
serum samples from patients.39 Therefore, the increased expression 
of miR-146a in the case of allergic inflammation might have limited 
influence on type-2 cell-mediated immune responses in a subgroup 
of AD patients with increased IgE.
Another miRNA that may influence the development of AD 
through its function in the immune system is miR-155. It was shown 
that miR-155 is overexpressed in the skin of AD patients, likely due 
F I G U R E  2   Overview of miRNAs discussed in this review. miRNAs are important regulators in allergic diseases. Herein, we provide an 
overview of the miRNAs described within the review and the cell types or organ systems where evidence of their actions has been reported. 
All miRNAs have been examined in human cells unless indicated in bold italics (mouse studies) or underlined italics (human and mouse)
figure
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to infiltrating immune cells, and suggested that miR-155 may in-
fluence the development of AD through the downregulation of 
cytotoxic T lymphocyte-associated antigen 4 (CTLA4), a negative 
regulator of T-cell activation.37 In addition, miR-155 expression was 
reported to positively correlate with AD severity, the number of 
Th17 cells, IL-17 mRNA expression and IL-17 plasma concentration, 
indicating that miR-155 may influence AD pathogenesis through 
its effect Th17 cells.42,43 The expression changes and effects in 
cell cultures of other miRNAs, including miR-151a, -143, -124, and 
-10a, are reported and outlined in Table 1. Altogether, the studies 
of miRNAs in AD clearly demonstrate that miRNAs affect the se-
verity of skin inflammation, modulate cellular responses of kerat-
inocytes and specialized immune cells and thereby influence the 
pathogenesis of AD.
2.2 | Allergic rhinitis
AR represents the most common allergic disease and is character-
ized by increased allergic symptoms along with circulating allergen-
specific IgE levels and/or positive skin prick test. This is triggered 
by various environmental allergens including pollen, molds, house 
dust mite and animal dander, resulting in a cascade of type 2 im-
mune response in which type 2 cytokine production and eosinophil 
numbers are increased. AR, a condition of the upper airways, often 
coexists with inflammation of the lower airways.44,45 Mucosal in-
flammation in AR and asthma shares many features, which has led 
to the “united airway concept”46 and the idea that inflammation in 
AR can progressively extend to the lower airways.47 Even though 
AR and asthma often co-exist, many studies examining AR subjects 
aimed to uncover unique AR-specific miRNA signatures (Table 2). 
Indeed, a subset of circulating miRNAs in plasma, miR-206, -338-
3p, -329, and -26a, were found to be differentially expressed in pa-
tients with AR, but not in healthy individuals or those with asthma. 
Random forest model prediction suggested that a subset of six 
miRNAs allowed for high accuracy in distinguishing between these 
three groups.48
In nasal biopsies, out-of-season AR patients displayed higher 
miR-7 and miRPlus-E1194 expression, whereas let-7, miR-498,-
187, -874, -143, -886, -224, and -767 were decreased compared to 
non-allergic patients undergoing inferior turbinate surgery.49,50 The 
reduced levels of let-7e were confirmed by an additional study, which 
also showed increased levels of miR-155, a miRNA involved in type 
2 immune responses (see above51,52), miR-205 and miR-498 in nasal 
biopsies of patients with current AR symptoms.50 miR-498 was also 
increased in the nasal mucosa of subjects suffering from perennial 
allergy, while miR-18a expression was significantly lower in subjects 
with perennial allergy compared to subjects responding to seasonal 
allergens.48
The diagnostic power of miRNAs was studied in relation to AR 
symptom severity (Total Nasal Symptoms Score) using microarray 
which revealed 3 down-regulated (miR-572, -1228-, -483) as well 
as 9 up-regulated miRNAs in nasal mucosa (miR-1908, -126, -92a, 
-125a, 19a, 26a, 106a, -181c, -3177). Of the identified miRNAs, 
miR-126, -19a, and -26a specifically and sensitively predicted AR 
disease activity in a receiver operating characteristic (ROC) analy-
sis,53 particularly when miR-126, -19a, and 26a were used in com-
bination. Taken together, several miRNAs were associated with AR, 
of which only let-7 and miR-26a were identified in independent 
studies.
miRNA Function Targets References
miR-21 Upregulated in AD ND 33
miR-146a Upregulated in the skin and keratinocytes 
of AD patients; alleviates chronic 




miR-155 May influence the development of AD by 
downregulating CTLA-4 in T cells and by 
modulation of the development of Th17 
cells
CTLA-4, SOCS1 37,42
miR-151a Altered in the blood plasma of AD 
patients, may contribute to Th2 skewing 
and pathogenesis of AD
IL12RB2 176
miRNA-143 May reduce the influence of IL-13 on 
epidermal keratinocytes
IL-13Rα1 177
miR-124 Suggested to decrease inflammation in 
chronic AD skin lesions
p65 178
miR-223 Upregulated in whole blood of AD 
patients
ND 148
miR-10a Upregulated in AD skin, inhibits 
keratinocyte proliferation
MAP3K7, HAS3 179
Note: ND—not determined in publications cited in the current table, may be described by other 
studies.
TA B L E  1   The functions of miRNAs in 
atopic dermatitis
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2.3 | Asthma
Asthma is a heterogeneous, chronic disease of the lower airways as-
sociated with airway hyper-reactivity, bronchoconstriction, cough, 
wheeze and, in the majority of cases, inflammation. The most com-
mon and well-studied form of asthma is the allergic type affecting 
both children and adults. Allergic asthma is associated with increased 
circulating allergen-specific IgE levels and/or positive skin prick test 
and triggered by various allergens in addition to airway hyper-re-
activity. This allergen-trigger leads to a cascading type 2 immune 
response in which type 2 cytokine production, eosinophil numbers 
and IgE levels are all increased. Given the vast heterogeneity of 
asthma sub-phenotypes, this section will focus primarily on findings 
regarding the role of miRNAs in allergic asthma (Table 3).
Allergic asthma often begins in early life with up to half of adults 
reporting asthma symptoms in childhood.54 Several studies exam-
ined the composition of miRNAs in the circulation and their potential 
as biomarkers. For example, 122 circulating miRNAs differentiated 
asthmatic from non-asthmatic children.55 The comprehensive in-
clusion of phenotypic characteristics in the Childhood Asthma 
Management Program (CAMP) studies allowed for the identification 
of miRNAs, through microarray analysis, that could potentially aid in 
the treatment of childhood asthma.56-58 These miRNAs correlated 
to lung function parameters after stratification by sex (miR-126, 
miRNA Function Targets Citations
let-7 Major regulatory mechanism for 





miR-206 Regulator of the VEGF pathway S100A7A 48
VEGF
miR-338-3p Inhibitor of Wnt/β-catenin signaling 
and inducer of epithelial-mesenchymal 
transition
WNT/ β -Catenin 48
miR-329 Unknown TGF-β1 48
miR-26a Modulation of TGF-β-dependent signaling 
pathways and repression of inflammatory 
responses by promoting regulatory T-cell 
responses or through NF-κB inhibition
SMAD2, SMAD3 48
miR-7 Unknown CMKLR1 49
miR-498 Suppressing Th17 cell differentiation via 
STAT3
STAT3 48,50
miR-187 Regulation of T-cell response via CD276 CD276 49,50
miR-143 Regulates memory T-cell differentiation TGF-β1 49,50
miR-886 Regulates TGF pathway via SMAD3 SMAD3, FoxO1 49,50
miR-224 Regulates TGF pathway via SMAD4 SMAD4 49,50
miR-155 Important role in host defense, modulates 
IL-13 pathway in macrophages 
determining the M2 phenotype
IL13Ra1 51,52,181,182
miR-205 Activation of ERK17 pathway MICAL2 50
miR-572 Regulates type-1 cytokine expression SOCS1 53
miR-1228 Regulates type 2 responses PPAR 53
miR-483 Inhibition of TGFβ1 TGFβ1 53
miR-1908 Inhibition of TGFβ1 SMAD2, SMAD3
MMP2
53
miR-126 Counter-regulation of IL4 effect VEGF, IRS1 53
miR-92a Regulation of IL4 effect WNT5a 53
miR-125a Dampens TLR pathway via IL10, suppresses 
A20
TLR, A20 53
miR-19a Activates TGFβ signaling TGFβ1 53
miR-106a Regulation of autophagic activity NOD1/2 53





miR18a Regulating TGF pathway CTGF 48
TA B L E  2   miRNAs in allergic rhinitis
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-139, -15b, -186, -342, -374a, -409, -660, -942, male associated and 
miR-126, -1290, -142, 191, female associated) and to bronchial hy-
per-responsiveness in response to methacholine challenge (miR-296, 
-16, and -30d). Applying machine learning to miRNA expression and 
the clinical asthma score from the CAMP cohort, these studies sug-
gested a combination of miRNAs as asthma prediction markers (miR-
146b, miR-206 and miR-720).58
Studies in adult asthma have also identified numerous miRNAs 
that may assist in better identifying and understanding the disease. 
Significantly decreased expression of let-7a, miR-21, -133a, -155, 
-328, and -1248 were found in exhaled breath condensates from 
asthmatic individuals compared to healthy subjects. Furthermore, 
numerous type 2 mediators were predicted targets of these miR-
NAs, suggesting their role in asthma.59 The dysregulation of miR-
21 in circulation and the airways has been commonly reported in 
allergic asthma, and thoroughly studied in humans and mice.9-11 
Certain miRNA expression was shown to be altered in a temporal 
manner with miR-155 found to be downregulated in sputum lym-
phocytes from allergic asthmatics only during pollen season.60 This 
raises the question as to which other miRNAs may be altered upon 
pollen exposure. miR-19a, another miRNA often altered in asthma, 
has multiple roles in the asthmatic airway.61-63 Increased expression 
of miR-19a in airway T cells promoted type 2 cytokine production 
through direct targeting of Phosphatase and Tensin Homolog (PTEN) 
and TNF Alpha Induced Protein 3 (TNFAIP3) and reduced miR-19a 
in the airway smooth muscle cells led to enhanced airway remodel-
ing.61,63 In a recent study, decreased epithelial and sputum miR-221 
were associated with eosinophilic airway inflammation in asthma.64 
Even out of the airways, miRNAs have shown potential as predictive 
markers in asthma. A study identified a set of plasma miRNAs, miR-
125b, -16, -299, -206, and -133b, that distinguished asthmatics from 
healthy individuals and subjects with AR.48 Recent studies in blood 
TA B L E  3   miRNAs in asthma—studies using patient samples and cell cultures
miRNA Function or findings Targets Citations
miR-15b, 126, -139,-142, -186,-191, 
-342, -374a, -409, -660, -942, -1290
Circulating miRNAs (blood) correlating to lung function 
parameters in children
ND 56
miR-16, -30d, -296 Circulating miRNAs (blood) correlating to bronchial 
hyper-responsiveness
ND 57
miR-146a, -206, -720 Circulating miRNAs (blood) used in combination as potential 
asthma prediction markers
ND 58
miR-16, -125b, -133b, -206, -299 Plasma miRNAs able to distinguish asthmatics from healthy 
individuals or those with allergic rhinitis
ND 48
let-7a, miR-21, -133a, -155, -328, -1248 Decreased in exhaled breath condensates from asthmatic 
compared to healthy subjects
ND 59
miR-21 Dysregulated in circulation and lungs in allergic experimental 
murine models and human allergic asthmatics
ND 9-11
miR-155 Downregulated in the lymphocytes of allergic asthmatics during 
pollen season
ND 60
miR-19a Increased in airway T cells.
Reduction in smooth muscle cells leads to enhanced remodeling
PTEN, A20 57,61
miR-221 Decreased levels in epithelial and sputum was associated with 
eosinophilic airway inflammation in asthma
ND 64
miR-185 Identified in circulating eosinophils as a distinguisher between 
healthy and asthmatic subjects. A potential predictor of 
asthma severity in blood sera
ND 66
miR-16 Negatively correlates to lung function parameters ADRB2 70
miR-223, -513a and -625 Downregulated in the blood of dust mite allergic asthmatics 




let-7a Abundant in the lungs and regulates IL-13 expression IL-13 72
miR-1248 Interacts with the 3′UTR to promote IL-5 expression IL-5 73
miR-15a Low levels in CD4+ T cells in pediatric asthma subject VEGF 74
miR-146a Downregulated in bronchial brushing samples of asthma 
patients, inhibits IL-8 and CXCL1 expression and neutrophil 
migration
IRAK1 153
miR-210 Increases in human mast cells following IgE sensitization ND 183
miR-155, -146a, miR-223, -374a Serum miRNAs correlating to clinical parameters in asthma 
subgroups
ND 65
Note: ND—not determined in publications cited in the current table, may be described by other studies 
     |  7WEIDNER Et al.
serum used miRNAs to identify asthma subgroups65 and another 
identified miR-185, a circulating eosinophil derived miRNA, to be a 
predictor of asthma severity.66
Numerous biomarker studies have been conducted to find both 
extracellular vesicle derived miRNAs from bronchoalveolar lavage 
(BAL) and cell-specific miRNAs dysregulated in asthma.67-69 Recently, 
more detailed studies have identified potential miRNA targets, sug-
gesting that multiple signaling processes may be affected. A negative 
correlation between lung function parameters and miR-16 in asthma 
was recently identified.70 In silico analysis predicted Adrenoreceptor 
B-2 (ADRB2), which is involved in bronchial smooth muscle contrac-
tion, as a target gene for miR-16 and was later confirmed by lucifer-
ase assay.70 Bioinformatic analysis of miRNA targets from the blood 
of house dust mite allergic asthmatic children revealed enrichment in 
the PI3K and NF-κB pathways. More specifically, correlations were 
shown between their target miRNAs and three genes: the Cbl Proto-
Oncogene (CBL), PPARG Coactivator 1 Beta (PPARGC1B) and the es-
trogen receptor 1 (ESR1), suggesting that these pathways and genes 
have a role in asthma pathogenesis.71 Additionally, miRNA expres-
sion in asthma has been correlated to expression and/or targeting of 
the type 2 cytokines,59,61 IL-13 72 and IL-5,73 as well as VEGF,74 key 
molecules in asthma pathogenesis, strengthening the evidence for 
their role in the regulation of the disease. Having shown the alter-
ation of a large set of miRNA in asthma calls for further investigation 
to mechanistically define their role(s) in asthma pathogenesis.
3  | ENVIRONMENTAL FAC TORS
3.1 | miRNAs in the regulation of virus-induced 
asthma exacerbation
Viruses affecting the respiratory system, such as human rhinoviruses 
(RVs), respiratory syncytial virus (RSV) and influenza, are known to 
cause serious illness and exacerbation in asthma patients.75-77 When 
infecting human bronchial epithelial cells (HBECs), these viruses ac-
tivate the NF-κB pathway and interferon signaling in order to induce 
cellular responses, restrict virus replication and avoid tissue damage. 
It has been suggested that HBECs of asthmatic patients might have 
weakened interferon responses, resulting in increased viral propa-
gation, enhanced activation of NF-κB and immune responses and 
asthma exacerbations.78 In this context, it can be envisioned that 
miRNAs targeting the NF-κB pathway and influencing interferon 
signaling may have great potential to modulate cellular responses 
to respiratory viruses and influence the exacerbation of asthma. 
Accordingly, one of the earliest studies addressing the question of 
miRNA involvement in the regulation of viral responses showed an 
increase in viral replication of RV-1B in HBECs when DICER was 
knocked down and, additionally, miR-128 and -155 were inhibited.79 
Another study found that miR-18a, -27a, -128, and -155 were down-
regulated in asthmatic HBECs and that simultaneous knockdown of 
these four miRNAs led to a significant increase in IL-8 and IL-6 expres-
sion.80 Differences in the bronchial epithelium of asthmatic patients 
may also occur due to epigenetic changes.81 miRNAs can influence 
genes involved in epigenetic regulation or modification and may also 
influence cellular responses to respiratory viruses. Indeed, a recent 
study demonstrated the upregulation of miR-22 and downregulation 
of its target genes histone deacetylase (HDAC)4 and CD147 in re-
sponse to influenza A virus H1N1 in bronchial epithelial cells from 
healthy subjects. However, cells from asthmatic patients were inca-
pable of upregulating miR-22 and showed increased and unchanged 
levels of HDAC4 and CD147, respectively.82 Several additional stud-
ies suggest important functions for miRNAs in the regulation of cel-
lular and immune responses to respiratory viruses (Table 4). Three 
miRNAs from different families (miR-24, -124a, -744) all interfere 
with the p38MAPK pathway through the downstream kinases MK2 
and Myc. MK2 and Myc are essential pro-viral host factors and their 
downregulation by these miRNAs (or small interfering RNA [siRNAs]) 
confers broad-spectrum antiviral activity against influenza A virus, 
RSV and adenovirus.83 Recently more studies have utilized primary 
respiratory epithelial cultures, including air-liquid interface cultures, 
clinical samples and in vivo mouse models84 possibly leading to bet-
ter clarification of the functions of miRNAs also during respiratory 
viral infections and virus-induced asthma exacerbations.
3.2 | The role of air pollution in miRNA regulation
In addition to viral infections, air pollution and cigarette smoke expo-
sure are important contributors to asthma development and/or ex-
acerbations.85-93 Air pollution is not only associated with aggravated 
type 2 responses, but can also lead to elevated neutrophil levels 
which are also a source of miRNAs.94 Since exposure to air pollution 
alters miRNA expression both in the lungs and in blood (reviewed 
in Ref. 95), this could represent an important immunomodulatory 
mechanism in asthma. However, studies that investigate miRNA ex-
pression and function in association with air pollution and allergy 
or asthma are scarce (Table 5). In bronchial brushings from atopic 
individuals exposed to diesel exhaust and allergen, miR-183, -324, 
and -132 expression was modulated by allergen exposure, but not 
by diesel exhaust.96 Diesel exhaust exposure on the other hand in-
creased expression of miR-21, -30e, -215, and -144 in blood of mild 
asthmatics. Importantly, miR-21 and miR-144 expression was associ-
ated with increased oxidative stress markers and reduced antioxi-
dant gene expression.97 Increased miR-155 in the serum of asthmatic 
children correlated with particulate matter level exposure.98 Indirect 
exposure by maternal smoking reduced miR-199a expression in cord 
blood. Interestingly, miR-199a targets the receptor tyrosine kinase 
AXL, which is more methylated upon maternal smoking and the com-
bination of maternal smoking and AXL methylation modifies the risk 
of childhood bronchitis symptoms.99 Tobacco smoke exposure is also 
associated with increased miR-223 expression in maternal and cord 
blood and with low numbers of regulatory T cells, which could be 
important in asthma development.100 This miRNA was also identi-
fied in induced sputum of patients with severe asthma (both atopic 
and non-atopic) and was associated with increased neutrophils.101 
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In lung tissue of murine models with in utero smoke exposure com-
bined with allergen challenge, the expression of miR-221, -16, -155, 
-21, and -18a was increased, whereas miR-130a expression was 
reduced compared to lungs challenged with allergen only.102,103 
Similarly, using miRNA arrays it was demonstrated that 133 miRNAs 
were dysregulated in fetal murine lungs upon maternal smoking.104 
Subsequent bioinformatic network analyses that included miRNAs 
and transcriptional regulators revealed insulin-like growth factor (Igf-
1) as a major hub. Dysregulation of IgF-1 was confirmed in PBMCs 
of healthy school-aged children with early-life smoke exposure.104 
In a murine cockroach asthma model, particulate matter exposure 
led to increased inflammatory responses, which were associated 
with elevated expression of miR-206. This miRNA targets the anti-
oxidant enzyme superoxide dismutase 1 (SOD1) leading to induction 
of oxidative stress, which may drive the pollution-driven aggravated 
inflammatory response.105 Expression analysis and functional ex-
periments in epithelial cells (primary and cell lines) exposed to air 
pollution have revealed miRNA involvement in several processes 
that can be important in asthma, such as oxidative stress, apopto-
sis, autophagy, NF-κB signaling and epithelial to mesenchymal tran-
sition (Figure 3).106-118 miRNAs reported to be involved in chronic 
obstructive pulmonary disease (reviewed in Ref. 119-121) may also 
TA B L E  4   miRNAs and respiratory viruses
miRNA Function Targets References
miR-155 Inhibition results in increased replication of RV-1B in HBECs. ND 79,83





miR-155,-27a, -18a, -128 Altered in asthmatic HBECs, simultaneous knockdown results 
in increased IL-8 and IL-6.
Alter viral responses in bronchial epithelial cell line
multiple 79
miRNA-4776 Downregulation of the NF-κB inhibitor beta, increased. 
Influenza A virus survival in HBECs
NFKBIB 184
miR-221 Downregulated in response to RSV, inhibits viral replication 
and infectivity
NGF, TrKA 185
miR-23b Downregulates very low density lipoprotein receptor and 
thereby inhibits infection by minor group of RVs
VLDLR, LRP5 186
miR-136 Increased in A549 human lung epithelial cells infected with 
H5N1 influenza A virus, upregulates IFN-β
RIG-I 187
miR-29 Induced in A549 cells by influenza A and PBMCs in influenza 
patients, induces COX2 and IFN-λ
DNMT3A 188
miR-29c Induced by influenza in A549 cells, may contribute to virus-
mediated apoptosis, inhibits innate immune responses
BCL2L2 189,190
miR-let-7c Upregulated in influenza infected A549 cells, may reduce virus 
replication
viral M1 191
miR-449b Upregulated in influenza infected A549 cells, regulates 
antiviral cytokine signaling
HDAC1 192
miR-3145 May inhibit influenza A virus replication viral PB1 193
miR-485 Prevents spurious activation of antiviral signaling, restricts 
influenza virus H5N1 infection
RIG-I, viral PB1 194
miR-144 Attenuates the host response to influenza virus by targeting 
the TRAF6-IRF7 signaling axis
TRAF6 195
miR-324-5p Downregulated in A549 cells in response to infection with 






Suppress influenza A (all) and RSV (miR-124a, miR-744) 
infection in A549 cells by inhibition of p38 MAPK expression 




miR-146a Increased in response to H3N2, targets TRAF6 in human nasal 
epithelial cells.
Decreases IFN-stimulated gene expression and enhances 





miRNA-126a, miRNA-16 and 
miRNA-21
Serum levels significantly lower during exacerbation visit as 
compared to follow-up visit
ND 199
Note: ND—not determined in publications cited in the current table, may be described by other studies.
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TA B L E  5   miRNA studies investigating the relation between pollution and allergy or asthma





In controlled exposures in atopic subjects (exposure chamber), the miRNA expression was modulated by 






In controlled exposures in asthma patients (exposure chamber), diesel exposure was associated with 
increased expression of miR-21, miR-30e, miR-215, and miR-144.
miR-144 and miR-21 associated with systemic oxidative stress markers and negative correlation between 
miR-144 and antioxidant genes
97
miR-199a1 (down) miR-199a controls AXL (receptor kinase of the TAM (TYRO3, AXL, MERTK) family. Maternal smoking is 
associated with increased methylation of AXL and with reduced expression of miR-199a. Combination of 
material smoking and increased AXL methylation alters the risk of childhood bronchitis symptoms
99







In a model cigarette-aggravated allergic asthma (in utero side stream cigarette smoke, followed by 






In a model cigarette-aggravated allergic asthma (in utero side stream cigarette smoke, followed by 
Aspergillus fumigatus exposure), these miRNAs are positively associated with Type2 cytokines in 
bronchoalveolar lavage fluid
103
F I G U R E  3   The effect of air pollution on miRNA networks and pathways in airway epithelial cells. Shown is a detailed schematic of 
miRNA action including known targets. Increased miRNA expression is indicated with upward red arrow, and decreased miRNA expression 
is indicated with downward blue arrow. Black arrows indicate a stimulatory effect on expression or process, and black line ending with 
perpendicular line indicates inhibitory effect. Smoke, pink and yellow figures represent air pollutants that may affect epithelial cells. Based 
on references 106-118 figure
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be important in asthma aggravated by air pollution. Although the 
actual involvement of these miRNAs in asthma remains to be further 
investigated, they could become interesting tools for exposure and 
risk assessment.
4  | MECHANISTIC STUDIES
The availability of miRNA-mimics, -inhibitors, and -knockout (KO) 
murine lines, in particular, have helped to delineate the impact 
of deregulated miRNA expression on disease pathology and re-
vealed intricate interactions of altered miRNA-regulation (Table 6). 
Mechanistic studies performed in murine models and human cell cul-
ture have broadened our understanding of miRNAs and have paved 
the way for future translational studies.
4.1 | miRNAs in innate immune responses in allergic 
airway inflammation
The exposure to allergens, for example, house dust mite (HDM), is 
an important trigger for changes in lung-specific miRNA expression. 
Allergen contact triggers epithelial release of IL-33, which in turn 
tightly controls the activation and proliferation of innate lymphoid 
type 2 cells (ILC2). ILC2s provide early release of type2-promoting 
IL-5 and IL-13 and initiate allergic airway inflammation. Studies in 
miRNA-KO mice revealed the importance of miRNAs in these early 
pathogeneic events. Mice deficient in miR-155 exposed to allergen 
had reduced levels of IL-33 in the airways post allergen challenge and 
lower ILC2 numbers compared to wild-type mice, revealing a criti-
cal role in inducing ILC2 proliferation.122 In dendritic cells (DC), lack 
of miR-155 led to reduced chemotaxis and type 2-priming capacity, 
resulting in ameliorated hallmarks of experimental asthma.41,123-125 
A similar phenotype was observed for ILC2s recovered from miR-
17~92 cluster deficient mice. These cells were found to be defective 
in growth and cytokine expression in response to IL-33 and thymic 
stromal lymphopoietin (Tslp).126 However, further studies revealed 
the complexity within miRNA-clusters, showing that individual family 
members can have opposing roles. For example, within the miR-17~92 
cluster, the family member mir-19a was found to be elevated in aller-
gic inflammation and shown to promote IL-5 and IL-13 production by 
targeting the known inhibitors SocS1 and Tnfaip3.126 In contrast, miR-
19b was downregulated in allergic inflammation and shown to target 
Tslp. Treatment with miR-19b was able to reduce allergic inflamma-
tion, providing evidence for a suppressive role and limiting type 2-in-
flammation.127 Another miRNA induced in the murine airway upon 
allergen contact and Toll-like receptor (TLR) signaling was miR-126. 
Inhibition of miR-126 using antagomirs was sufficient to suppress the 
inflammatory response, implicating a prominent role in driving type 2 
inflammation.128,129 The inflammatory milieu in the lung induced the 
expression of miR-21 in cells of the monocyte/macrophage lineage 
and structural cells. miR-21 targets IL-12p35 mRNA and thereby criti-
cally controls the type 1/type 2 balance in type 2-high (Ovalbumin 
[OVA], HDM, Aspergillus fumigatus) and steroid-insensitive experi-
mental asthma.130-133 Furthermore, it was shown that inhibition of 
miR-9 in experimental allergic, steroid resistant asthma models re-
stored the steroid sensitivity via targeting protein phosphatase 2 
regulatory subunit B (B56) δ isoform (Ppp2r5d).134 miR-9 was also 
increased in the sputum of patients with neutrophilic asthma, which 
is often associated with steroid resistance. Additionally, miRNAs 
seem to control macrophage differentiation into their intrinsic sub-
phenotypes. Along this line, miR-511 was increased in alternatively 
activated macrophages, but decreased in pro-inflammatory mac-
rophages.135 A similar study identified an upregulation of miR-124 in 
alternatively activated macrophages136 and in CD14+CD16+ mono-
cytes of patients with asthma compared to controls.
4.2 | miRNAs controlling adaptive immunity in 
experimental asthma
In vitro studies in CD4+ T cells revealed a dynamic change of 
miRNA expression upon activation of cells and polarization into 
specialized CD4+ T-cell subsets.137 Some miRNAs involved in con-
trolling the polarization process are encoded in the polycistronic 
clusters Mirc11 and Mirc22, comprising miRs-23(a/b), -24 and 
-27(a/b). Bioinformatic analyses revealed several genes in a net-
work upstream of IL-4 to be among the targets for these miRNAs. 
In an acute model of experimental asthma, mice bearing CD4+ T 
cells deficient in these miRNAs developed an augmented type 2 
response, including high type 2-cytokine levels and elevated eo-
sinophil numbers in BAL.11,138 Conversely, miR-145 expression was 
found induced in inflamed lungs and seemed to actively promote 
and sustain the inflammatory process. Indeed, blockade by an-
tagomirs suppressed the production of IL-5 and IL-13 in the lungs 
and inhibited the inflammatory phenotype to an extent equal to 
dexamethasone.139
Once established, the allergic phenotype is thought to stabilize 
and reinforce itself by IL-13 production in the inflamed environ-
ment. Cellular control mechanisms, that restrict IL-13 expression in 
the airways, seem to be suppressed in allergic airway inflammation 
and include the involvement of miRNAs. One example is the let-7 
family of miRNAs,140 all of which were found to be downregulated 
in OVA-induced experimental asthma. Exogenous delivery of let-7 
limited eosinophil recruitment and histopathological alterations and 
airway-reactivity to methacholine.140 The let-7 miRNA family is also 
very abundant in the lung and their inhibition in vivo ameliorated mu-
rine experimental asthma.72 However, in an additional study, let-7a 
was shown to inhibit IL-13 expression by directly targeting Il-13140 
in vitro and exogenous administration of a let-7 microRNA mimic al-
leviated asthmatic features in a mouse model of asthma. Additional 
examples that are both downregulated in OVA-induced asthma lung 
tissue are miR-133a and miR-488 which directly target the genes 
IGF-1 receptor (Igf1r)141 and Tgfβ1,142 respectively. Furthermore, 
overexpression of both miRNAs was able to reduce remodeling as-
sociated genes.
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4.3 | Cell-based functional studies
Several studies investigated miRNA-based molecular mechanisms 
ex vivo/in vitro in different cell types involved in asthma patho-
genesis.143-148 miR-155 was shown to be induced by hyper-stretch 
in human bronchial epithelial cells149 and targets Src homology 
2 domain–containing inositol 5-phosphatase 1 (SHIP1) produc-
tion and activates Janus Kinase (JNK) signaling leading to KC (the 
functional IL-8 paralog) secretion in mouse models. miR-181b was 
decreased in bronchial brushings and plasma from patients with 
asthma and inversely correlated with eosinophil counts in spu-
tum.150 Overexpressing this miRNA in a bronchial epithelial cell 
line (BEAS-2B) confirmed the regulation of the target Secreted 
Phospho Protein 1 (SPP1) and reduced IL-13 induced secretion of 
IL-1β and CC-Motif Chemokine Ligand 11 (CCL11). In this line, miR-
181b was induced following addition of dexamethasone. Further, 
miR-27b has been described to be decreased in HDM induced ex-
perimental asthma, with a proposed function in the regulation of the 
PI3K-AKT pathway via targeting Spleen Associated Tyrosine Kinase 
(SYK) and Epidermal Growth Factor Receptor (EGFR) in a bronchial 
epithelial cell line (16-HBE).55 In concordance to its effect in skin 
keratinocytes,35,36 miR-146a was shown to have anti-inflammatory 
function in human lung alveolar epithelial cell line A549151,152 and 
in HBECs.68,153-157 Interestingly, it was recently shown that primary 
human airway epithelial cells secrete miRNAs in extracellular vesi-
cles (EV)154 as a means of intercellular communication by function-
ally transferring miRNAs to recipient cells.155 The miRNA content 
of epithelial EVs was altered when the cells were treated with IL-
13, suggesting a differential regulation of target genes in recipient 
cells. Further, EVs isolated from BALF68 or plasma156 of patients with 
asthma contained different miRNAs compared to healthy individu-
als. This ability of miRNAs to be transferred between different cells 
adds another layer of complexity to their involvement in perpetuat-
ing anasthmatic response in the airways.157
Besides epithelial cells, several studies have investigated 
miRNA-regulated mechanisms in airway smooth muscle cells 
TA B L E  6   miRNAs and mouse models
miRNA Function Target Reference
miR-21 Induced by Th2 cytokines in DC and macrophages and 
promotes type 2- driven inflammation
IL-12p35 130-133
miR-126 Induced in airway wall and promotes type 2 
inflammation
TOM1 128,129
let-7a-e Downregulated in CD4+ T cells and suppresses type 2 
inflammation
IL-13 140
miR- 145 Induced by allergen exposure and promotes type 2 
inflammation
139
miR-155 Induced in ILC2 in type 2 inflamed airways and 
neutralization ameliorates experimental asthma 
phenotype.
Involved in Th2-mediated airway inflammation.





miR-23~27 Type 2 cells lacking this miR-cluster express elevated 
type 2 cytokines
Gene network regulating IL-4 11,138
miR-17-92 Mice deficient in this miR-cluster develop an 
augmented experimental asthma phenotype
126
miR-19a Upregulated in asthmatic airways and promotes 
experimental asthma
SOCS1/A20 61
miR-19b Downregulated in asthmatic airways. Exogenous 









A miR-network is induced in lung-resident type 2 cells 
and comprises a combination of induced miRs-27b 
and -23b as well as silenced miR-206, miR106b, and 
miR-203. Antagonism of expression levels reduces 
type 2 cytokine expression
Fine tuning of multiple pathways, 
that suppress inhibitory signals and 
allow activation and survival of 
type 2 cells
164
miR-1 Downregulated by VEGF. Intranasal miR-1 delivery 
inhibited inflammatory responses in experimental 
asthma models
Mpl 201,202
miR-221 Influences effector functions and actin cytoskeleton in 
mast cells
ND 203
Note: ND—not determined in publications cited in the current table, may be described by other studies.
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(hASMCs). In vitro stimulation of hASMCs with a cytokine cocktail 
(IL-1β, TNF-α, IFN-γ) caused an increase in miR-146a with the ob-
served effect being stronger in asthmatic donor cells than healthy 
controls.158 As inhibition of miR-146a increases cyclooxygenase-2 
(COX-2) levels and IL-1β secretion by hASMCs, the authors sug-
gested that miR-146a may be an interesting anti-inflammatory 
factor in asthma. In line with this study, upregulation of miR-145 
in hASMCs was demonstrated upon cytokine stimulation and was 
associated with enhanced migration and proliferation in vitro.159 
Inhibition of miR-145 reversed this effect through the reduced ex-
pression of collagen type I and contractile protein MHC via tar-
geting of Krüppel-like factor 4 (KLF-4). Finally, miR-21 was shown 
to modulate hASMCs proliferation in vitro, via targeting PTEN, as 
identified by lentiviral overexpression experiments.160 miR-21 has 
been previously associated with asthma development, mainly due 
its targeting of, that is, IL-12p35,130,161 highlighting the multi-func-
tional roles of miRNAs in several cell types contributing synergisti-
cally to asthma pathology.
4.4 | miRNA effects in gene networks
miRNA expression analyses from isolated cells, as well as in tissues 
from disease models, revealed simultaneously altered expression for 
several miRNAs. This implicates several parallel regulatory events 
which are not captured by traditional miRNA-single target gene 
identification methodologies. Recently, network methods have been 
utilized to assess the outcome of miRNA-regulation from a global 
perspective, revealing possible relationships between the miRNA-
targets and affected biological pathways. An example of such com-
prehensive regulatory miRNA-mRNA networks has been simulated 
for in vitro differentiated Th17 cells. Compared to naive CD4+ T cells, 
Th17 cells expressed lower levels of miR-106a, miR-18b and miR-363 
all belonging to the miR-106a~363 cluster.162 Overexpression of the 
aforementioned miRNAs led to decreased expression of their con-
firmed target genes Nuclear Factor of Activated T cells (Nfat5), RAR 
related Orphan Receptor C (Rorc), and Rorα; entailing decreased Th17 
differentiation and IL-17 secretion, therefore identifying this miRNA 
cluster as a potential target for Th17-mediated inflammation. Th17 
cell differentiation is also controlled by the miR-17~92 cluster, in par-
ticular by miR-18a,163 which targets Smad4, hypoxia-inducible factor 
1α (Hif1α), and Rorα. Thus, miR-18a deficiency enhances Th17 differ-
entiation in vitro and increases Th17 cells in tissue in experimental 
asthma models in vivo.
Another approach identified a distinct miRNA-expression pat-
tern in tissue-resident type 2 cells in experimental allergic asthma.164 
Compared to naïve CD4+ T cells, type 2 cells in inflamed lungs dis-
played a strong downregulation of miRNAs164 and this expression 
pattern changed with the transition from acute to chronic airway in-
flammation. Integrating gene and miRNA expression using a network 
approach, revealed distinct disease stage specific gene-miRNA net-
works.164 Pathogenic type 2 responses were predicted to result from 
combined and cumulative miRNA activities. Type 2 inflammation 
was predicted to result from elevated miR-27b and miR-23b, target-
ing immune regulatory Tgfb1 and Egfr pathways on the one hand and 
on the other hand, reduced expression of miR-206, miR-106b and 
miR-203, allowing for the expression of genes involved in immune 
activation. Antagonizing this ex vivo miRNA-expression pattern in 
vitro using miRNA-inhibitors and mimics suppressed IL-13 expres-
sion in Th2 cells and supported the in silico predictions of an intricate 
network of miRNA regulation.164
Notably, we have mainly discussed the influence of miRNAs in 
the regulation of the immune response in allergic diseases. However, 
as individual miRNAs influence a wide range of targets and path-
ways, it is only logical to assume that several other pathways, such 
as, for example, metabolic pathways, might be affected at the same 
time and are also relevant for asthma pathogenesis.
5  | CONCLUSION
miRNA research, thus far, has led to a breadth of information and 
long lists of potentially interesting miRNAs, but mechanistic stud-
ies of miRNA targeting and function are only beginning to emerge. 
Furthermore, it is unlikely that one miRNA alone holds the key to 
explain the pathology of asthma or allergic diseases. More likely, 
there are numerous players and complex networks of interactions 
that lead not only to disease pathogenesis, but also to heteroge-
neity, making mechanistic insight into the roles of miRNAs all the 
more important going forward. We propose that understanding 
common triggers that change miRNA expression in distinct cell 
populations, at defined disease stages and in specific phenotypes, 
together with assessing the net effects of miRNAs will help to 
decipher the pathophysiological consequences of altered miRNA 
expression in allergic diseases. Nonetheless, we have provided im-
portant evidence highlighting a crucial role of miRNA in the patho-
genesis of asthma and allergic disease, making them interesting 
targets for clinical investigations. As asthma and allergy are very 
heterogeneous conditions and because current treatments are still 
inefficient in controlling severe forms of these diseases, more in-
dividualized and effective therapies are in a great demand.165-167 
Interest in novel therapeutics strategies to target single miR-
NAs128,129,139,168-170 is increasing as well as the interest in using 
miRNA profiles as biomarkers for (lung) disease.48,58,65,66,171-174 
To implement the use of miRNAs as biomarkers, they should be 
specific, have the capacity to predict disease phenotypes, and be 
easily detectable in body fluids. Several studies mentioned in this 
review (eg, CAMP study) demonstrate that miRNAs indeed have 
this potential. We will address the challenges and potential pit-
falls associated with the use of miRNAs as biomarkers in a future 
review.
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G LOSSARY
AGO2—a member of the Argonaute family of proteins that plays a 
central role in RNA silencing through the binding of small RNAs such 
as miRNAs.
DCGR8—a nuclear protein required for mRNA processing. 
DCGR8 binds to Drosha and forms a complex that cleaves the pri-
mary transcript known as pri-miRNA into a characteristic stem-loop 
structure known as a pre-miRNA.
Drosha—a nuclear RNase III that cleaves primary miRNAs 
(pri-miRNAs) to release hairpin-shaped pre-miRNAs.
Dicer—a cytoplasmic RNase III that cuts the pre-miRNA to form 
mature miRNA.
pre-miRNA hairpin—precursor-miRNAs (pre-miRNA) refer to the 
hairpin precursors of miRNAs formed by the cleavage of primary 
miRNAs by DCGR8 and Drosha.
miRNA duplex—the sense and antisense strand of the pre-
miRNA hairpin that is cleaved to a double stranded RNA. One strand 
will ultimately be degraded.
miRISC—The RNA-induced silencing complex is a ribonucleop-
rotein complex comprised of proteins such as Dicer, Ago2 and TRBP 
and miRNA. The miRISC will target an mRNA for post-transcriptional 
regulation.
Polycistronic clusters—a primary transcript encoding more than 
one miRNA or mRNA.
Antagomirs—a class of chemically engineered oligonucleotides 
that are used to silence endogenous miRNA.
Biomarker—A biological molecule found in fluid or tissue that al-
lows for the identification of a specific condition/disease.
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